1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 5
FEATURED COMPANIES
- Abbott Laboratories
- AbbVie Inc.
- Bayer AG
- Cipla Inc.
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- MORE
The urinary tract infection treatment market is poised to grow by $786.71 million during 2020-2024 progressing at a CAGR of 2% during the forecast period.
This report on the urinary tract infection treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
The market is driven by the relation of UTI with several other factors leading to rising incidence rate of UTI, rising cases of hospital-acquired UTI and unmet demand due to lack of available treatment for MDR microorganisms. In addition, relation of UTI with several other factors leading to rising incidence rate of UTI is anticipated to boost the growth of the market as well.
The urinary tract infection treatment market analysis includes type segment and geographical landscapes.
The urinary tract infection treatment market is segmented as below:
By Type
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
This report on the urinary tract infection treatment market covers the following areas:
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
The analyst's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
This report on the urinary tract infection treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
The market is driven by the relation of UTI with several other factors leading to rising incidence rate of UTI, rising cases of hospital-acquired UTI and unmet demand due to lack of available treatment for MDR microorganisms. In addition, relation of UTI with several other factors leading to rising incidence rate of UTI is anticipated to boost the growth of the market as well.
The urinary tract infection treatment market analysis includes type segment and geographical landscapes.
The urinary tract infection treatment market is segmented as below:
By Type
- Uncomplicated UTI
- Complicated UTI
- Asia
- Europe
- North America
- ROW
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
This report on the urinary tract infection treatment market covers the following areas:
- Urinary tract infection treatment market sizing
- Urinary tract infection treatment market forecast
- Urinary tract infection treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
The analyst's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- Abbott Laboratories
- AbbVie Inc.
- Bayer AG
- Cipla Inc.
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- MORE
Executive Summary
Geographic Landscape
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019-2024 ($ million)
13: Global market: Year-over-year growth 2019-2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Other1 - Market share 2019-2024 (%)
22: Comparison by Other1
23: Uncomplicated UTI - Market size and forecast 2019-2024 ($ million)
24: Uncomplicated UTI - Year-over-year growth 2019-2024 (%)
25: Complicated UTI - Market size and forecast 2019-2024 ($ million)
26: Complicated UTI - Year-over-year growth 2019-2024 (%)
27: Market opportunity by Other1
28: Customer Landscape
29: Market share by geography 2019-2024 (%)
30: Geographic comparison
31: Asia - Market size and forecast 2019-2024 ($ million)
32: Asia - Year-over-year growth 2019-2024 (%)
33: Europe - Market size and forecast 2019-2024 ($ million)
34: Europe - Year-over-year growth 2019-2024 (%)
35: North America - Market size and forecast 2019-2024 ($ million)
36: North America - Year-over-year growth 2019-2024 (%)
37: ROW - Market size and forecast 2019-2024 ($ million)
38: ROW - Year-over-year growth 2019-2024 (%)
39: Key leading countries
40: Market opportunity by geography ($ million)
41: Impact of drivers and challenges
42: Vendor landscape
43: Landscape disruption
44: Industry risks
45: Vendors covered
46: Market positioning of vendors
47: Abbott Laboratories - Overview
48: Abbott Laboratories - Business segments
49: Abbott Laboratories - Key offerings
50: Abbott Laboratories - Key customers
51: Abbott Laboratories - Segment focus
52: AbbVie Inc. - Overview
53: AbbVie Inc. - Business segments
54: AbbVie Inc. - Key offerings
55: AbbVie Inc. - Key customers
56: AbbVie Inc. - Segment focus
57: Bayer AG - Overview
58: Bayer AG - Business segments
59: Bayer AG - Key offerings
60: Bayer AG - Key customers
61: Bayer AG - Segment focus
62: Boehringer Ingelheim International GmbH - Overview
63: Boehringer Ingelheim International GmbH - Business segments
64: Boehringer Ingelheim International GmbH - Key offerings
65: Boehringer Ingelheim International GmbH - Key customers
66: Boehringer Ingelheim International GmbH - Segment focus
67: Cipla Inc. - Overview
68: Cipla Inc. - Business segments
69: Cipla Inc. - Key offerings
70: Cipla Inc. - Key customers
71: Cipla Inc. - Segment focus
72: GlaxoSmithKline Plc - Overview
73: GlaxoSmithKline Plc - Business segments
74: GlaxoSmithKline Plc - Key offerings
75: GlaxoSmithKline Plc - Key customers
76: GlaxoSmithKline Plc - Segment focus
77: Merck & Co. Inc. - Overview
78: Merck & Co. Inc. - Business segments
79: Merck & Co. Inc. - Key offerings
80: Merck & Co. Inc. - Key customers
81: Merck & Co. Inc. - Segment focus
82: Novartis AG - Overview
83: Novartis AG - Business segments
84: Novartis AG - Key offerings
85: Novartis AG - Key customers
86: Novartis AG - Segment focus
87: Pfizer Inc. - Overview
88: Pfizer Inc. - Business segments
89: Pfizer Inc. - Key offerings
90: Pfizer Inc. - Key customers
91: Pfizer Inc. - Segment focus
92: SHIONOGI Co. Ltd. - Overview
93: SHIONOGI Co. Ltd. - Business segments
94: SHIONOGI Co. Ltd. - Key offerings
95: SHIONOGI Co. Ltd. - Key customers
96: SHIONOGI Co. Ltd. - Segment focus
97: Currency conversion rates for US$
98: Research Methodology
99: Validation techniques employed for market sizing
100: Information sources
101: List of abbreviations
- Market Overview
- Market ecosystem
- Market characteristics
- Value chain analysis
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019-2024
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segments
- Comparison by Disease type
- Uncomplicated UTI - Market size and forecast 2019-2024
- Complicated UTI - Market size and forecast 2019-2024
- Market opportunity by Disease type
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- Asia - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- North America - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
- Vendor landscape
- Landscape disruption
- Competitive scenario
- Vendors covered
- Market positioning of vendors
- Abbott Laboratories
- AbbVie Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Cipla Inc.
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- SHIONOGI Co. Ltd.
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019-2024 ($ million)
13: Global market: Year-over-year growth 2019-2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Other1 - Market share 2019-2024 (%)
22: Comparison by Other1
23: Uncomplicated UTI - Market size and forecast 2019-2024 ($ million)
24: Uncomplicated UTI - Year-over-year growth 2019-2024 (%)
25: Complicated UTI - Market size and forecast 2019-2024 ($ million)
26: Complicated UTI - Year-over-year growth 2019-2024 (%)
27: Market opportunity by Other1
28: Customer Landscape
29: Market share by geography 2019-2024 (%)
30: Geographic comparison
31: Asia - Market size and forecast 2019-2024 ($ million)
32: Asia - Year-over-year growth 2019-2024 (%)
33: Europe - Market size and forecast 2019-2024 ($ million)
34: Europe - Year-over-year growth 2019-2024 (%)
35: North America - Market size and forecast 2019-2024 ($ million)
36: North America - Year-over-year growth 2019-2024 (%)
37: ROW - Market size and forecast 2019-2024 ($ million)
38: ROW - Year-over-year growth 2019-2024 (%)
39: Key leading countries
40: Market opportunity by geography ($ million)
41: Impact of drivers and challenges
42: Vendor landscape
43: Landscape disruption
44: Industry risks
45: Vendors covered
46: Market positioning of vendors
47: Abbott Laboratories - Overview
48: Abbott Laboratories - Business segments
49: Abbott Laboratories - Key offerings
50: Abbott Laboratories - Key customers
51: Abbott Laboratories - Segment focus
52: AbbVie Inc. - Overview
53: AbbVie Inc. - Business segments
54: AbbVie Inc. - Key offerings
55: AbbVie Inc. - Key customers
56: AbbVie Inc. - Segment focus
57: Bayer AG - Overview
58: Bayer AG - Business segments
59: Bayer AG - Key offerings
60: Bayer AG - Key customers
61: Bayer AG - Segment focus
62: Boehringer Ingelheim International GmbH - Overview
63: Boehringer Ingelheim International GmbH - Business segments
64: Boehringer Ingelheim International GmbH - Key offerings
65: Boehringer Ingelheim International GmbH - Key customers
66: Boehringer Ingelheim International GmbH - Segment focus
67: Cipla Inc. - Overview
68: Cipla Inc. - Business segments
69: Cipla Inc. - Key offerings
70: Cipla Inc. - Key customers
71: Cipla Inc. - Segment focus
72: GlaxoSmithKline Plc - Overview
73: GlaxoSmithKline Plc - Business segments
74: GlaxoSmithKline Plc - Key offerings
75: GlaxoSmithKline Plc - Key customers
76: GlaxoSmithKline Plc - Segment focus
77: Merck & Co. Inc. - Overview
78: Merck & Co. Inc. - Business segments
79: Merck & Co. Inc. - Key offerings
80: Merck & Co. Inc. - Key customers
81: Merck & Co. Inc. - Segment focus
82: Novartis AG - Overview
83: Novartis AG - Business segments
84: Novartis AG - Key offerings
85: Novartis AG - Key customers
86: Novartis AG - Segment focus
87: Pfizer Inc. - Overview
88: Pfizer Inc. - Business segments
89: Pfizer Inc. - Key offerings
90: Pfizer Inc. - Key customers
91: Pfizer Inc. - Segment focus
92: SHIONOGI Co. Ltd. - Overview
93: SHIONOGI Co. Ltd. - Business segments
94: SHIONOGI Co. Ltd. - Key offerings
95: SHIONOGI Co. Ltd. - Key customers
96: SHIONOGI Co. Ltd. - Segment focus
97: Currency conversion rates for US$
98: Research Methodology
99: Validation techniques employed for market sizing
100: Information sources
101: List of abbreviations
Note: Product cover images may vary from those shown
3 of 5
FEATURED COMPANIES
- Abbott Laboratories
- AbbVie Inc.
- Bayer AG
- Cipla Inc.
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- MORE
The analyst recognizes the following companies as the key players in the global urinary tract infection treatment market: Abbott Laboratories, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Cipla Inc., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., and SHIONOGI Co. Ltd.
According to one of the team's analysts: The latest trend gaining momentum in the market is growing awareness of controlled usage of antibiotics.
According to the report, one of the major drivers for this market is the relation of uti with several other factors leading to rising incidence rate of uti.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
According to one of the team's analysts: The latest trend gaining momentum in the market is growing awareness of controlled usage of antibiotics.
According to the report, one of the major drivers for this market is the relation of uti with several other factors leading to rising incidence rate of uti.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
- Abbott Laboratories
- AbbVie Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Cipla Inc.
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- SHIONOGI Co. Ltd.
Note: Product cover images may vary from those shown
5 of 5
LOADING...
